GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Medical
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Location:
United States
Description:
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Language:
English
Episodes
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
5/3/2024
Dr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)
Duration:00:03:02
Barriers to Biomarker Testing: Cost and Insurance
4/27/2024
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Duration:00:03:30
Barriers to Biomarker Testing: Ordering Tests
4/20/2024
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC
Duration:00:06:23
The Adaura Trial: The Effect on EGFR+ Treatment
4/15/2024
Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.
Duration:00:06:26
Biomarker Driven Therapy for NSCLC
4/13/2024
Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.
Duration:00:05:13
Current Recommendations and Best Practices for Biomarker Testing
4/11/2024
Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.
Duration:00:03:53
The Importance of Biomarker Testing: What is Liquid Biopsy?
4/9/2024
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Duration:00:04:55
Biomarkers in NSCLC
4/8/2024
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Duration:00:05:55
Key Points from the Adaura Trial: Osimertinib
11/30/2023
Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.
Duration:00:06:14
Biomarkers in NSCLC
11/23/2023
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Duration:00:05:55
The Importance of Biomarker Testing: What is Liquid Biopsy?
11/16/2023
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Duration:00:04:55
Barriers to Biomarker Testing: Cost and Insurance
11/9/2023
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Duration:00:03:30
Neoadjuvant Treatment for Patients with NSCLC
10/27/2023
Dr. Joshua Reuss examines data on neoadjuvant targeted therapy.
Duration:00:03:11
The Alina Trial for ALK+ NSCLC
10/21/2023
Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC.
Duration:00:01:13
Local Therapy for Limited Metastatic NSCLC
10/17/2023
Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).
Duration:00:04:17
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
10/10/2023
Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.
Duration:00:02:05
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
10/3/2023
Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.
Duration:00:01:59
Local Therapy for NSCLC Patients After Frontline Therapy
9/27/2023
Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.
Duration:00:07:52
The Role of the Patient as Advocate
9/24/2023
Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.
Duration:00:02:59
Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
9/20/2023
Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.
Duration:00:03:12